Please login to the form below

Not currently logged in
Email:
Password:

Flex Pharma appoints new R&D president

William McVicar joins from Inotek

Flex Pharma has appointed William McVicar as its new president of research and development, in a role that will focus on advancing clinical trials in MS, ALS and Charcot-Marie-Tooth.

McVicar has 30 years of clinical development experience, most recently serving at Inotek in various roles such as executive VP of pharmaceutical development, chief scientific officer and president.

He said: “It is my great pleasure to be joining the Flex team that is applying the scientific advances of a Novel laureate to improving the lives of patients living with debilitating neurological diseases.

“In partnership with CMO Tom Wessel, my former Sepracor colleague, we are poised to execute on our US phase II development plans.”

Prior to his time at Inotek, McVicar has held roles in several pharmaceutical companies such as Sepracor, Sandoz, Novartis and Rhone Poulenc Rorer.

Christoph Westphal, CEO at Flex Pharma, said: “Bill has an impressive track record of multiple drug approvals based upon his operational excellence and execution.

“With their successful partnership from their time at Sepracor, Bill and our CMO, Dr Tom Wessel, are a great team to rapidly advance our phase II clinical trials in MS, ALS and Charcot-Marie-Tooth with FLX-787 which will be amongst the most advanced clinical programs in ALS and CMT.”

6th April 2017

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

3 reasons why clinical trials will thrive in 2021
It’s not often that a single event can change the trajectory of an entire system, yet that is exactly what has happened to healthcare systems across the world and clinical...
#DemandDiversity: New research on COVID-19 clinical trial perceptions within minorities and high-risk populations
Lack of diversity in clinical trials still remains on of the biggest issues for COVID-19 clinical trials. But despite the growing discussions, calls for change, growing regulatory guidance and much...
Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...

Infographics